Cholesterol, statins and cancer

Clinical and Experimental Pharmacology and Physiology

Volumn 34, Issue 3, 2007, Pages 135-141

  Brown, Andrew J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Akt; Cholesterol; Hedgehog; Patched; Statins; Steroid hormones; Sterol regulatory element binding protein (SREBP); Vitamin D

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVALONIC ACID; PRAVASTATIN; PROTEIN KINASE B; SONIC HEDGEHOG PROTEIN; STEROID HORMONE; STEROL REGULATORY ELEMENT BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL CYCLE; CHOLESTEROL METABOLISM; COLORECTAL CANCER; DRUG MECHANISM; HOMEOSTASIS; HUMAN; LIPID RAFT; PROSTATE CANCER; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; CASE-CONTROL STUDIES; CELL CYCLE; CHOLESTEROL; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEMBRANE MICRODOMAINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RISK; SIGNAL TRANSDUCTION; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 33846448142     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2007.04565.x     Document Type: Short Survey

References (56)

1. Webb JH. Cancer, its nature and treatment. Lancet 1901; ii: 976 (Letter).
2. White C. On the occurrence of crystals in tumours. J. Pathol. Bacteriol. 1909; 13: 3-10.
3. Bischoff F. Carcinogenesis through cholesterol and derivatives. Prog. Exp. Tumor Res. 1963; 25: 412-44.
4. Chen HW, Kandutsch AA, Heiniger HJ. The role of cholesterol in malignancy. Prog. Exp. Tumor Res. 1978; 22: 275-316.
5. Byers T, Nestle M, McTiernan A et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J. Clin. 2002; 52: 92-119.
6. Kritchevsky SB, Kritchevsky D. Serum cholesterol and cancer risk: An epidemiologic perspective. Annu. Rev. Nutr. 1992; 12: 391-416.
7. Bravi F, Scotti L, Bosetti C et al. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann. Oncol. 2006; 17: 1014-17.
8. Poynter JN, Gruber SB, Higgins PD et al. Statins and the risk of colorectal cancer. N. Engl. J. Med. 2005; 352: 2184-92.
9. Shannon J, Tewoderos S, Garzotto M et al. Statins and prostate cancer risk: A case-control study. Am. J. Epidemiol. 2005; 162: 318-25.
10. Ahmed MH, Osman MM, Alokail MS. Statins and breast cancer: A smoking gun or guilt by association? Expert Opin. Drug Saf. 2006; 5: 599-601.
11. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: A meta-analysis. JAMA 2006; 295: 74-80.
12. Duncan RE, El-Sohemy A, Archer MC. Statins and the risk of cancer. JAMA 2006; 295: 2720.
13. Freeman MR, Solomon KR, Moyad M. Statins and the risk of cancer. JAMA 2006; 295: 2720-1.
14. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat. Rev. Cancer 2005; 5: 930-42.
15. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006; 11: 306-15.
16. Simons K, Ikonen E. How cells handle cholesterol. Science 2000; 290: 1721-6.
17. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. Cell 2006; 124: 35-46.
18. Horton JD, Shah NA, Warrington JA et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl Acad. Sci. USA 2003; 100: 12 027-32.
19. Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. Mol. Cell 2002; 10: 237-45.
20. Kuwabara PE, Labouesse M. The sterol-sensing domain: Multiple families, a unique role? Trends Genet. 2002; 18: 193-201.
21. Goldstein JL, Rawson RB, Brown MS. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. Arch. Biochem. Biophys. 2002; 397: 139-48.
22. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-64.
23. Demoulin JB, Ericsson J, Kallin A, Rorsman C, Ronnstrand L, Heldin CH. Platelet-derived growth factor stimulates membrane lipid synthesis through activation of phosphatidylinositol 3-kinase and sterol regulatory element-binding proteins. J. Biol. Chem. 2004; 279: 35 392-402.
24. Zhou RH, Yao M, Lee TS, Zhu Y, Martins-Green M, Shyy JY. Vascular endothelial growth factor activation of sterol regulatory element binding protein: A potential role in angiogenesis. Circ. Res. 2004; 95: 471-8.
25. Hegarty BD, Bobard A, Hainault I, Ferre P, Bossard P, Foufelle F. Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c. Proc. Natl Acad. Sci. USA 2005; 102: 791-6.
26. Porstmann T, Griffiths B, Chung YL et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005; 24: 6465-81.
27. Du X, Kristiana I, Wong J, Brown AJ. Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: A link between a key cell proliferative pathway and membrane synthesis. Mol. Biol. Cell 2006; 17: 2735-45.
28. Heemers HV, Verhoeven G, Swinnen JV. Androgen activation of the SREBP pathway: Current insights. Mol. Endocrinol. 2006; 20: 2265-77.
29. Yang T, Espenshade PJ, Wright ME et al. Crucial step in cholesterol homeostasis. Sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002; 110: 489-500.
30. Heemers H, Verrijdt G, Organe S et al. Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor. J. Biol. Chem. 2004; 279: 30 880-7.
31. Herr I, Pfitzenmaier J. Glucocorticoid use in prostate cancer and other solid tumours: Implications for effectiveness of cytotoxic treatment and metastases. Lancet Oncol. 2006; 7: 425-30.
32. Osterlund T, Kogerman P. Hedgehog signalling: How to get from Smo to Ci and Gli. Trends Cell Biol. 2006; 16: 176-80.
33. Cooper MK, Wassif CA, Krakowiak PA et al. A defective response to Hedgehog signaling in disorders of cholesterol biosynthesis. Nat. Genet. 2003; 33: 508-13.
34. Kelleher FC, Fennelly D, Rafferty M. Common critical pathways in embryogenesis and cancer. Acta Oncol. 2006; 45: 375-88.
35. Wicking C, McGlinn E. The role of hedgehog signalling in tumorigenesis. Cancer Lett. 2001; 173: 1-7.
36. Datta S, Datta MW. Sonic Hedgehog signaling in advanced prostate cancer. Cell Mol. Life Sci. 2006; 63: 435-48.
37. Karhadkar SS, Bova GS, Abdallah N et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004; 431: 707-12.
38. Riobo NA, Lu K, Ai X, Haines GM, Emerson Jr CP. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc. Natl Acad. Sci. USA 2006; 103: 4505-10.
39. Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothened by patched-dependent (pro-) vitamin D3 secretion. Public Library Sci. Biol. 2006; 4: e232.
40. Lindstrom E, Shimokawa T, Toftgard R, Zaphiropoulos PG. PTCH mutations: Distribution and analyses. Hum. Mutat. 2006; 27: 215-19.
41. Holick MF. Vitamin D: Its role in cancer prevention and treatment. Prog. Biophys. Mol. Biol. 2006; 92: 49-59.
42. Adolphe C, Hetherington R, Ellis T, Wainwright B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 2006; 66: 2081-8.
43. Fernandez C, Martin M, Gomez-Coronado D, Lasuncion MA. Effects of distal cholesterol biosynthesis inhibitors on cell proliferation and cell cycle progression. J. Lipid Res. 2005; 46: 920-9.
44. Suarez Y, Fernandez C, Ledo B, Martin M, Gomez-Coronado D, Lasuncion MA. Sterol stringency of proliferation and cell cycle progression in human cells. Biochim. Biophys. Acta 2005; 1734: 203-13.
45. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 1972; 175: 720-31.
46. Simons K, Ikonen E. Functional rafts in cell membranes. Nature 1997; 387: 569-72.
47. Murata M, Peranen J, Schreiner R, Wieland F, Kurzchalia TV, Simons K. VIP21/caveolin is a cholesterol-binding protein. Proc. Natl Acad. Sci. USA 1995; 92: 10 339-43.
48. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am. J. Physiol. Cell Physiol. 2005; 288: C494-506.
49. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. 2005; 115: 959-68.
50. Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr. Opin. Clin. Nutr. Metab. Care 2006; 9: 379-85.
51. Freeman MR, Cinar B, Lu ML. Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol. Metab. 2005; 16: 273-9.
52. Chinnaiyan P, Harari PM. Clinical advancement of EGFR inhibitors in cancer therapy. Methods Mol. Biol. 2006; 327: 189-202.
53. Karpen HE, Bukowski JT, Hughes T, Gratton JP, Sessa WC, Gailani MR. The sonic hedgehog receptor patched associates with caveolin-1 in cholesterol-rich microdomains of the plasma membrane. J. Biol. Chem. 2001; 276: 19 503-11.
54. Garcia MJ, Reinoso RF, Sanchez Navarro A, Prous JR. Clinical pharmacokinetics of statins. Methods Find. Exp. Clin. Pharmacol. 2003; 25: 457-81.
55. Caner M, Sonmez B, Kurnaz O et al. Atorvastatin has cardiac safety at intensive cholesterol-reducing protocols for long term, yet its cancer-treatment doses with chemotherapy may cause cardiomyopathy even under coenzyme-Q10 protection. Cell Biochem. Funct. 2006; 14 August (Epub ahead of print): DOI:10.1027/cbf.1356.
56. Jones PJ. Statin rebound effect? J. Lab. Clin. Med. 2003; 141: 235-6.